Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New HIV vaccine holds promise of global effectiveness

14.11.2002


Clinical tests began today of a novel vaccine directed at the three most globally important HIV subtypes, or clades. Developed by scientists at the Dale and Betty Bumpers Vaccine Research Center (VRC), part of the National Institute of Allergy and Infectious Diseases (NIAID), the vaccine incorporates HIV genetic material from clades A, B and C, which cause about 90 percent of all HIV infections around the world.



"This is the first multigene, multiclade HIV vaccine to enter human trials," notes NIAID Director Anthony S. Fauci, M.D. "It marks an important milestone in our search for a single vaccine that targets U.S. subtypes of HIV as well as clades causing the global epidemic," he adds.

"This trial begins a process that we hope will culminate in a globally effective HIV vaccine," says Gary Nabel, M.D., Ph.D., who heads the VRC. "The first step is to develop a multiclade vaccine. If our candidate elicits an effective immune response and proves safe in clinical testing, we will include additional components in subsequent trials in hopes of boosting this response. Ultimately, we aim to build a potent vaccine designed to prevent HIV infection."


The trial vaccine is a DNA vaccine, a kind shown to be very safe in previous clinical trials. It incorporates parts of four HIV genes. Three of these vaccine components are modified versions of HIV genes called gag, pol and nef taken from clade B, the subtype that predominates in Europe and North America. The fourth vaccine component is derived from an HIV gene named env.

The env gene codes for a protein on the outer coat of the virus that allows it to recognize and attach to human cells. VRC scientists are the first to combine modified env from clades A and C, which are the most common in Africa, as well as from clade B. A single vaccine combining multiple env components from different HIV subtypes could, in theory, be effective in many places in the world.

While these gene fragments can stimulate an immune response, they cannot reconstitute themselves into an infectious virus. A person cannot become infected with HIV from this vaccine, Dr. Nabel emphasizes.

Efforts to develop a broadly effective vaccine against HIV are complicated not only by the many clades, but also by the virus’ ability to elude immune system defenses through rapid mutation. "Any HIV vaccine must hit a constantly moving target," says Dr. Nabel. "Essentially, we are trying to enlarge that target through a multiclade vaccine." Researchers do not yet know if a multiclade vaccine will be more effective than one based on a single clade. "That is one question we hope our vaccine trials will eventually answer," notes Dr. Nabel.

The public plays a critical role in this ongoing research, says Barney Graham, M.D., Ph.D., chief of the VRC’s clinical trials core and lead investigator in the multiclade vaccine trial. "We want the community to understand and support the process of vaccine development so that together we can attain the goal of stopping or slowing the AIDS pandemic," he says. "Although thousands have already volunteered to take part in HIV vaccine trials, many more are needed. The importance of community participation cannot be overemphasized," says Dr. Graham.

The first phase of the trial, which is being conducted at the National Institutes of Health in Bethesda, MD, is meant to determine the vaccine’s safety and will enroll 50 healthy, HIV-negative volunteers. Following an extensive informed consent process, volunteers, who must be between 18 and 40 years old to participate, will be vaccinated with either the test vaccine or an inactive saline solution in a series of increasing doses. Neither the participants nor the researchers will know which group a participant is in. During the yearlong trial, scientists will assess the vaccine’s safety and note if it induces any immune response in the vaccinees. Expanded tests conducted through NIAID’s HIV Vaccine Trials Network are planned for several domestic sites as well as sites in Haiti and South Africa.

Anne Oplinger | EurekAlert!
Further information:
http://www.niaid.nih.gov/
http://www.clinicaltrials.gov
http://www.niaid.nih.gov/vrc

More articles from Health and Medicine:

nachricht New malaria analysis method reveals disease severity in minutes
14.08.2017 | University of British Columbia

nachricht New type of blood cells work as indicators of autoimmunity
14.08.2017 | Instituto de Medicina Molecular

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

A Map of the Cell’s Power Station

18.08.2017 | Life Sciences

Engineering team images tiny quasicrystals as they form

18.08.2017 | Physics and Astronomy

Researchers printed graphene-like materials with inkjet

18.08.2017 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>